Testing TRX319 for worsening multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of primary or secondary progressive multiple sclerosis (MS).
- Your MS must have been getting worse in the last 2 years, and you need to be able to walk (maybe with help) but use a wheelchair only part of the time.
- You must be between 18 and 65 years old.
- You cannot have had a relapse in the last year, or have active infections like hepatitis, HIV, or tuberculosis.
- You must be willing to use birth control and not donate blood for a year after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This study tests an experimental medicine called SUN-627 for people with progressive multiple sclerosis (MS) that is not currently flaring up. The goal is to see if it can slow down worsening disability without causing serious side effects.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This trial tests whether a simple, non-invasive treatment called remote ischemic conditioning — using brief cycles of a blood pressure cuff on your arm — can improve walking and slow disability in people with primary progressive MS. It targets people with moderate disability who have trouble walking.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.